[go: up one dir, main page]

AR109762A1 - TREATMENT OF PROSTATE CANCER, ORAL FORMULATION - Google Patents

TREATMENT OF PROSTATE CANCER, ORAL FORMULATION

Info

Publication number
AR109762A1
AR109762A1 ARP170102716A ARP170102716A AR109762A1 AR 109762 A1 AR109762 A1 AR 109762A1 AR P170102716 A ARP170102716 A AR P170102716A AR P170102716 A ARP170102716 A AR P170102716A AR 109762 A1 AR109762 A1 AR 109762A1
Authority
AR
Argentina
Prior art keywords
treatment
prostate cancer
oral formulation
methoxyurea
tetrahydrothien
Prior art date
Application number
ARP170102716A
Other languages
Spanish (es)
Inventor
Lynn Seely
David B Mlean
Brendan Mark Johnson
Vijaykumar Reddy Rajasekhar
Original Assignee
Myovant Sciences Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myovant Sciences Gmbh, Takeda Pharmaceuticals Co filed Critical Myovant Sciences Gmbh
Publication of AR109762A1 publication Critical patent/AR109762A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una formulación oral que comprende entre aproximadamente 80 mg y aproximadamente 480 mg de N-(4-(1-(2,6-difluorobencil)-5-((dimetilamino)metil)-3-(6-metoxi-3-piridazinil)-2,4-dioxo-1,2,3,4-tetrahidrotien[2,3-d]pirimidin-6-il)fenil)-N’-metoxiurea, o una cantidad correspondiente de una sal farmacéuticamente aceptable de la misma, para usar en un método de tratamiento del cáncer de próstata en un sujeto que lo necesita.Claim 1: An oral formulation comprising between about 80 mg and about 480 mg of N- (4- (1- (2,6-difluorobenzyl) -5 - ((dimethylamino) methyl) -3- (6-methoxy-3 -pyridazinyl) -2,4-dioxo-1,2,3,4-tetrahydrothien [2,3-d] pyrimidin-6-yl) phenyl) -N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt of the same, to use in a method of treatment of prostate cancer in a subject that needs it.

ARP170102716A 2016-09-30 2017-09-29 TREATMENT OF PROSTATE CANCER, ORAL FORMULATION AR109762A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662402004P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
AR109762A1 true AR109762A1 (en) 2019-01-23

Family

ID=65351687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102716A AR109762A1 (en) 2016-09-30 2017-09-29 TREATMENT OF PROSTATE CANCER, ORAL FORMULATION

Country Status (2)

Country Link
AR (1) AR109762A1 (en)
EA (1) EA201990843A1 (en)

Also Published As

Publication number Publication date
EA201990843A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
NI201800102A (en) LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PYRROLIDIN-1-IL) -PYRAZOLE [1,5-A] PYRIMIDIN-3-IL) -3 -HYDROXIPYRROLIDINE-1-CARBOXAMIDE.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
IL265700B1 (en) N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea and uses thereof
EP4520398A3 (en) Treatment of prostate cancer
CL2017003445A1 (en) Solid forms and formulations of imidazopyrazine compounds.
MX2021004639A (en) COMBINATIONS OF LYSINE-SPECIFIC DEMETHYLASE-1 INHIBITORS (LSD1) FOR USE IN THE TREATMENT OF SOLID TUMORS.
CL2007000601A1 (en) Compounds derived from pyrazolic heterobicycles, inhibitors of thyroxine kinase protein activity; pharmaceutical composition comprising said compounds; and use of the compounds in the treatment of a hyperproliferative disease.
CL2008001297A1 (en) N - [(1s) -1- (5-fluoropyrim idin-2-i1) ethyl] -3- (5-isopropoxy-1 h-pyrazol-3-yl) -3h-imidazo [4,5-b] pyridine -5amine or a pharmaceutically acceptable salt thereof; pharmaceutical composition comprising it; and its use in the treatment of cancer.
UY27712A1 (en) REPLACED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURES
CL2008003023A1 (en) (s) -4-amino-n- (1- (4-chlorophenyl) -3-hydroxypropyl) -1- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) piperidine-4-carboxamide, inhibitor protein kinase b; preparation procedure; intermediate compounds; pharmaceutical composition comprising said compound; and use for the treatment of cancer.
MX2016007111A (en) Inhibitors of bruton's tyrosine kinase.
MX2016012365A (en) Combinations.
CL2018002807A1 (en) Methods of treatment of pediatric cancers.
AR097556A1 (en) USE OF A COMBINATION OF A MEK INHIBITOR AND ERK INHIBITOR FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
CL2019002900A1 (en) Benzoazepine analogs as bruton tyrosine kinase inhibitors.
MX374724B (en) CARBAZOLE DERIVATIVES.
PE20170148A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND USE OF THEM FOR THE TREATMENT OF CANCER
MX2022001743A (en) SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUOR-1,2,3,4-TETRAHI DRONAFTALEN-2-IL)AMINO)-N-(1-(2-METHYL) -1-(NEOPENTYLAMINO)PROPAN-2- IL)-1H-IMIDAZOLE-4-IL)PENTANAMIDE AND USES THEREOF.
MX2023000187A (en) DOSAGE OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER.
IL308152A (en) 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CO2018002046A2 (en) New oral delayed dual dexlansoprazole oral composition
AR109762A1 (en) TREATMENT OF PROSTATE CANCER, ORAL FORMULATION
MX2016009226A (en) Pharmaceutical combinations.
CL2008001176A1 (en) Pharmaceutical combination comprising pregabalin and 1- (2-ethoxyethyl) -5- [ethyl (methyl) amino] -n-mesyl-7 - [(4-methyl-2-pyridyl) amino] -1h-pyrazole [4,3 -d] pyrimidine-3-carboxamide; pharmaceutical composition; and use of the combination for the treatment of pain.
AR108090A1 (en) LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PIRROLIDIN-1-IL) -PIRAZOLO [1,5-A] PIRIMIDIN-3-IL) -3 -HYDROXIPIRROLIDINA-1-CARBOXAMIDA

Legal Events

Date Code Title Description
FC Refusal
FC Refusal